Erschienen in:
01.09.2022 | Commentary
Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer
verfasst von:
Stergios A. Polyzos, Niki Katsiki
Erschienen in:
Hormones
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Excerpt
In a multicenter, phase II, open-label, randomized clinical trial (RCT) [
1], Alkhouri et al. assigned 108 patients with presumed NASH to five treatment groups for 24 weeks, as follows: (1) semaglutide [a glucagon-like peptide-1 receptor agonist (GLP-1RA)] monotherapy; (2) semaglutide and cilofexor [a farnesoid-X-receptor (FXR) agonist] 30 mg/d; (3) semaglutide and cilofexor 100 mg/d; (4) semaglutide and firsocostat [an acetyl-coenzyme A carboxylase (ACC) inhibitor] 20 mg/d; and (5) semaglutide, cilofexor 30 mg/d, and firsocostat 20 mg/d. Semaglutide was subcutaneously administered once weekly (0.24 mg to 2.4 mg) [
1]. …